SCHEMBL6318191

SCHEMBL6318191

O=C(O)[C@H](Cc1ccccc1)N(Cc1ccc(-c2ccc(Cl)cc2Cl)s1)C(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.59

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
SHMT1 P34896 1/20 0.40
PPARA Q07869 1/20 0.38
TMEM97 Q5BJF2 2/20 0.37
SIGMAR1 Q99720 2/20 0.37
HCAR2 Q8TDS4 1/20 0.37
PSMB5 P28074 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320128 1.00 SHMT1 (0.40) SHMT1PPARATMEM97SIGMAR1HCAR2
SCHEMBL6317283 0.90 PPARA (0.38) PPARATMEM97SIGMAR1
SCHEMBL6319972 0.88 ALDH1A1 (0.38) PPARA
SCHEMBL6316454 0.88 TP53 (0.38) PPARA
SCHEMBL6316449 0.88 TP53 (0.38) PPARA
SCHEMBL6318307 0.87 RORC (0.39)
SCHEMBL6315673 0.87 CYP3A4 (0.40) PPARA
SCHEMBL6318988 0.87 ACKR3 (0.38) PPARA
SCHEMBL6318993 0.87 ACKR3 (0.38) PPARA
SCHEMBL6315666 0.87 CYP3A4 (0.40) PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887877-B2 Compounds and methods for the treatment or prevention of Flavivirus infections VIROCHEM PHARMA INC. (CA) 2005-05-03 US claimed
US-20030229053-A1 Compounds and methods for the treatment or prevention of flavivirus infections SHIRE BIOCHEM INC. (CA) 2003-12-11 US claimed
US-6887877-B2 Compounds and methods for the treatment or prevention of Flavivirus infections VIROCHEM PHARMA INC. (CA) 2005-05-03 US disclosed
US-6858630-B2 Naphthimidazole derivatives and their use as thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2005-02-22 US disclosed
US-20030229053-A1 Compounds and methods for the treatment or prevention of flavivirus infections SHIRE BIOCHEM INC. (CA) 2003-12-11 US disclosed
US-20030083361-A1 Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia SMITHKLINE BEECHAM CORPORATION 2003-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083361-A1 Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia MPL, THPO, TPO SHMT1 3247/4885PPARA 2731/4885TMEM97 3358/4885
US-20030229053-A1 Compounds and methods for the treatment or prevention of flavivirus infections HAVCR2, ZC3HAV1, MAVS SHMT1 2213/4885PPARA 2311/4885TMEM97 2467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.